Results 61 to 70 of about 25,109 (253)

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy

Cells, 2021
Overexpression of members of the HER/erbB transmembrane tyrosine kinase family like HER2/erbB2/neu is associated with various cancers. Some heterodimers, especially HER2/HER3 heterodimers, are particularly potent inducers of oncogenic signaling.
Daniela Gutsch, Robert Jenke, Thomas Büch, Achim Aigner   +3 more
doaj   +1 more source

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Clinical Cancer Research, 2021
Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance are limited. HER3 mediates EGFR-TKI resistance.
K. Yonesaka, J. Tanizaki, O. Maenishi, K. Haratani, H. Kawakami, Kaoru Tanaka, H. Hayashi, K. Sakai, Y. Chiba, A. Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Y. Hashimoto, Kenji Hirotani, T. Kagari, K. Nishio, K. Nakagawa   +20 more
semanticscholar   +1 more source

Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer‐Predisposing Factors in Familial Early‐Onset Colorectal Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Colorectal cancer (CRC) has raised considerable health concerns worldwide, with increasing incidence rates, specifically among younger populations. Despite remarkable progress in diagnosing and treating various diseases, the genetic basis of CRC remains only partially understood.
Behnaz Bagheri, Neda Mohsen‐Pour, Najmeh Salehi, Pardis Ketabi Moghadam, Adel Zeinalpour, Amir Sadeghi, Samira Kalayinia, Nayeralsadat Fatemi   +7 more
wiley   +1 more source

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

Oncotarget, 2016
Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules.
Bon, G., Loria, R., Amoreo, C., Verdina, A., Sperduti, I., Mastrofrancesco, A., Soddu, S., Diodoro, M., Mottolese, M., TODARO, Matilde, STASSI, Giorgio, Milella, M., De Maria, R., Falcioni, R.   +13 more
openaire   +6 more sources

HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction. [PDF]

PLoS ONE, 2016
Overexpression of receptor tyrosine kinases (RTK), including members of the HER family, has prognostic and therapeutic significance in invasive esophagogastric carcinoma.
Brett L Ecker, Laura Taylor, Paul J Zhang, Emma E Furth, Gregory G Ginsberg, Matthew T McMillan, Jashodeep Datta, Brian J Czerniecki, Robert E Roses   +8 more
doaj   +1 more source

DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer

EMBO Molecular Medicine
Despite clinical benefits of tyrosine kinase inhibitors (TKIs) in cancer, most tumors can reactivate proliferation under TKI therapy. Here we present transcriptional profiling of HER2+ breast cancer cells transitioning from dormant drug tolerant cells to
Majid Momeny, Mari Tienhaara, Mukund Sharma, D. Chakroborty, Roosa Varjus, Iina Takala, J. Merisaari, A. Padzik, Andreas Vogt, I. Paatero, K. Elenius, T. Laajala, K. Kurppa, J. Westermarck   +13 more
semanticscholar   +1 more source

HER3 Is an Actionable Target in Advanced Prostate Cancer

Cancer Research, 2021
HER3 is an actionable target in prostate cancer, especially with anti-HER3 immunoconjugates, and targeting HER3 warrants clinical evaluation in prospective trials.
Veronica S. Gil, S. Miranda, R. Riisnaes, B. Gurel, M. d’Ambrosio, A. Vasciaveo, M. Crespo, A. Ferreira, Daniela Brina, M. Troiani, A. Sharp, Beshara Sheehan, R. Christova, G. Seed, I. Figueiredo, Maryou B. K. Lambros, D. Dolling, J. Rekowski, A. Alajati, M. Clarke, Rita Pereira, P. Flohr, Gemma Fowler, G. Boysen, S. Sumanasuriya, D. Bianchini, P. Rescigno, Caterina Aversa, N. Tunariu, Christina Guo, A. Paschalis, C. Bertan, Lorenzo Buroni, J. Ning, S. Carreira, P. Workman, A. Swain, A. Califano, Michael M. Shen, A. Alimonti, A. Neeb, J. Welti, W. Yuan, J. D. de Bono   +43 more
semanticscholar   +1 more source

Recent Progress in Treating Airway Mucus Hypersecretion by Targeting the Epidermal Growth Factor Receptor Signaling Pathway

Pediatric Discovery, EarlyView.
ABSTRACT Asthma, chronic pulmonary obstructive disease (COPD), cystic fibrosis, and acute respiratory infections are severe respiratory conditions that significantly contribute to global morbidity and mortality. Airway mucus hypersecretion is an important common pathophysiological and clinical manifestation of these diseases and is closely associated ...
Yuanyuan Zhang, Fuping Yang, Chunyu Yan, Yu Deng, Enmei Liu   +4 more
wiley   +1 more source

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers.

PLoS ONE, 2023
HER2 is over-expressed in around 15% to 20% of breast cancers. HER3 plays a critical role in HER2 mediated tumorigenesis. Increased HER3 transcription and protein levels occur upon inhibition of HER2. We aimed to identify proteins that bound to HER3 upon
Samar M Alanazi, Wasim Feroz, Rosalin Mishra, Mary Kate Kilroy, Hima Patel, Long Yuan, Sarah J Storr, Joan T Garrett   +7 more
doaj   +1 more source

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer

Nature Communications, 2021
Immune checkpoint blockade (ICB) therapy has revolutionized head and neck squamous cell carcinoma (HNSCC) treatment, but
Zhiyong Wang, Yusuke Goto, M. Allevato, Victoria H. Wu, R. Saddawi-Konefka, M. Gilardi, Diego Alvarado, B. Yung, Aoife O’Farrell, A. Molinolo, U. Duvvuri, J. Grandis, J. Califano, E. Cohen, J. Gutkind   +14 more
semanticscholar   +1 more source